Startups
The Investor Relations website contains information about YS Biopharma Co., Ltd.'s business for stockholders, potential investors, and financial analysts.
Mentions in press and media 22
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 16, 2024 | YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024 | GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliver... |
| Apr 9, 2024 | YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine | GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| Apr 3, 2024 | YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility | GAITHERSBURG, Md., April 3, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| Feb 14, 2024 | YS Biopharma Announces Appointment of New Directors | GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicat... |
| Jan 23, 2024 | YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024 | GAITHERSBURG, Md., Jan. 23, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to d... |
| Jan 8, 2024 | YS Biopharma Announces Changes to its Board Committees | GAITHERSBURG, Md., Jan. 8, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliverin... |
| Dec 21, 2023 | YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting | GAITHERSBURG, Md., Dec. 21, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| Nov 14, 2023 | Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target | GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
| Oct 31, 2023 | YS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccine | GAITHERSBURG, Md., Oct. 31, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and deliveri... |
Show more